Will AFFYMAX INCORPORATED (OTCMKTS:AFFY) Run Out of Steam Soon? Short Interest Is Down

October 12, 2017 - By Michael Collier

The stock of AFFYMAX INCORPORATED (OTCMKTS:AFFY) registered a decrease of 95.33% in short interest. AFFY’s total short interest was 4,900 shares in October as published by FINRA. Its down 95.33% from 104,900 shares, reported previously. With 16,100 shares average volume, it will take short sellers 0 days to cover their AFFY’s short positions.

About 2,240 shares traded. Affymax, Inc. (OTCMKTS:AFFY) has 0.00% since October 12, 2016 and is . It has underperformed by 16.70% the S&P500.

Affymax, Inc. is a biopharmaceutical company. The company has market cap of $1.41 million. The Company’s product OMONTYS is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. It has a 0.52 P/E ratio. OMONTYS is a synthetic, peptide erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells.

More notable recent Affymax, Inc. (OTCMKTS:AFFY) news were published by: Benzinga.com which released: “How to Protect Your Retirement Plans” on June 26, 2013, also Seekingalpha.com with their article: “Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen” published on August 28, 2013, Businesswire.com published: “Affymax Board Announces Decision to Dissolve the Company” on June 24, 2014. More interesting news about Affymax, Inc. (OTCMKTS:AFFY) were released by: Seekingalpha.com and their article: “Don’t Believe In Affymax – The Stock Is Probably Worthless” published on August 29, 2013 as well as Businesswire.com‘s news article titled: “Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a …” with publication date: November 26, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.